OncLive Staff

In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.

Gilberto De Lima Lopes, MD, discusses how he navigates challenges caused by COVID-19 to continue to provide optimal care to his patients with cancer.

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Toni K. Choueiri, MD, discusses the COVID-19 and Cancer Consortium, a multicenter effort to obtain evidence-based information on patients with cancer who have tested positive for the virus.

Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.

This week we have collaborated with Weill Cornell Medicine to highlight important topics facing oncologists today. Join us Saturday, June 6, 2020 at 11 AM EST.

An OncLive® Weekly Webinar Series highlighting best practices, treatment updates, and multidisciplinary approaches to ovarian cancer care through the COVID-19 pandemic. Join us Wednesday, June 3, 2020 at 8 PM EST.

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, June 2, 2020 at 8 PM EST.

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 26, 2020 at 8 PM EST.

Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 19, 2020 at 8 PM EST.

Robert G. Uzzo, MD, MBA, FACS, shares efforts to improve cancer care amidst the COVID-19 crisis.

In this third webinar of our series, we will take an in-depth look at systemic therapy and how the landscape of treatment continues to evolve during this time. Join us on Wednesday, May 20, 2020 at 8 PM EST.

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 19, 2020 at 8 PM EST.

This OncLive® webinar will focus on the impact of COVID-19 on oncology nursing care for patients with hepatocellular carcinoma. Join us on Wednesday May 18, 2020 at 8 PM EST.

This week we have collaborated with The University of Chicago Medicine to highlight important topics facing oncologists today. Join us Saturday, May 16, 2020 at 11 AM EST.

This week we have collaborated with The University of Chicago Medicine to highlight important topics facing oncologists today. Join us Saturday, May 16, 2020 at 11 AM EST.

An OncLive® Weekly Webinar Series highlighting best practices, treatment updates, and multidisciplinary approaches to ovarian cancer care through the COVID-19 pandemic. Join us Wednesday, May 13, 2020 at 8 PM EST.

Join oncologists nationwide who have learned from the top leaders in the lung cancer field as they share their insights on coronavirus disease 2019 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system. Join us Thursday, May 28, 2020 at 8 PM EST.

Balazs Halmos, MD, MS, provides insight into how his institution continues to adapt in response to the COVID-19 crisis.

Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.

Karen L. Reckamp, MD, MS, provides insight on how she is navigating challenges posed by the COVID-19 crisis.

Join top leaders in the lung cancer field as they share their insights on COVID-19 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system on Thursday, May 14, 2020 at 8 PM EST.

This week we have collaborated with NYU Langone Health to highlight important topics facing oncologists today. Join us on Saturday, May 9, 2020 at 11 AM EDT.

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.

Shilpa Gupta, MD, shares updates from the frontlines and discusses how she is handling the COVID-19 pandemic.

This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.

We had the pleasure of speaking with John L. Marshall, MD, who discussed the evolving treatment landscape of HER2-targeted treatment strategies in colorectal cancer.